Advanced Breast Cancer Clinical Trial
Official title:
Clinical Study of Plasmodium Immunotherapy for Advanced Breast Cancers and Advanced Liver Cancers
The purpose of this study is to evaluate the safety and preliminarily evaluate the effectiveness of Plasmodium immunotherapy for advanced breast cancers and advanced liver cancers.The treatment will last 4-6 weeks from the day of successful infection and will be terminated by antimalarial drugs.
This study is to enroll 30 patients in each type of cancer. Each patient will be vaccinated with P.vivax-infected red blood cells containing approximately 0.1-1.0 × 10^7 Plasmodium parasites and be observed for the exact infection time, parasitemia condition and infection course; principal clinical symptoms such as fever; gastrointestinal reaction; peripheral blood parameters; the changes in heart, lung, liver and kidney function. Preliminarily observe the changes in the primary and metastatic lesions of the cancer, the tolerance of patients to Plasmodium infection, changes in tumor-related parameters and immunological related parameters.The rate of the erythrocytes infected by plasmodium is controlled below 0.01% by using Artemisinin during the course, and clinical treatment is conduced according to the microscopic examination to ensure that no serious complications occurs.The duration of the planned treatment of each subject is 4-6 weeks. The time of the treatment course is based on vaccination with P.vivax-infected red blood cells. After 4-6 weeks, parasitemia will be terminated by antimalarial drugs for terminating the treatment of Plasmodium immunotherapy (the immunological treatment effect may persist after the termination of Plasmodium infection), and then the patients are followed up for 2 years. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653740 -
Omic Technologies to Track Resistance to Palbociclib in Metastatic Breast Cancer
|
N/A | |
| Completed |
NCT02091960 -
A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05156619 -
Health Care Disparities in Culturally Diverse, Special Needs & Disadvantaged Populations - Bridging the Gap
|
||
| Recruiting |
NCT05173103 -
Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer
|
||
| Withdrawn |
NCT05191004 -
Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC
|
Phase 1/Phase 2 | |
| Completed |
NCT00754325 -
Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor
|
Phase 2 | |
| Recruiting |
NCT04953377 -
PFMT Educational Intervention for Patients With Advancer Breast Cancer
|
N/A | |
| Completed |
NCT03240224 -
Bioinformation Therapy for Breast Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06193525 -
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
|
Phase 2 | |
| Completed |
NCT03312738 -
A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor
|
Phase 2 | |
| Active, not recruiting |
NCT05063786 -
Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
|
Phase 3 | |
| Recruiting |
NCT05655598 -
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02499146 -
Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04456855 -
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
|
||
| Completed |
NCT04408118 -
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC
|
Phase 2 | |
| Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT03205761 -
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT04316169 -
Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer
|
Phase 1 | |
| Completed |
NCT00546104 -
Phase II Dasatinib Study in Advanced Breast Cancer
|
Phase 2 |